Quick Answer
Trevi Therapeutics, Inc. reported Operating Income Loss of -$49.33 million for the year ending 2025.
- Trevi Therapeutics, Inc. showed an increase of +4.3% in Operating Income Loss from 2024 to 2025.
- This data is from Trevi Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 17, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$3.14 million | Q2 2018: -$4.38 million | Q3 2018: -$4.96 million | Q1 2019: -$4.81 million | Q2 2019: -$7.42 million | Q3 2019: -$7.65 million | Q1 2020: -$8.64 million | Q2 2020: -$7.41 million | Q3 2020: -$7.24 million | Q1 2021: -$8.09 million | Q2 2021: -$9.17 million | Q3 2021: -$6.95 million | Q1 2022: -$7.03 million | Q2 2022: -$7.82 million | Q3 2022: -$8.41 million | Q1 2023: -$7.56 million | Q2 2023: -$8.38 million | Q3 2023: -$9.05 million | Q1 2024: -$11.91 million | Q2 2024: -$13.29 million | Q3 2024: -$14.09 million | Q1 2025: -$11.47 million | Q2 2025: -$13.72 million | Q3 2025: -$13.92 million.
- Over the full 8 years of available data (2018 to 2025), Trevi Therapeutics, Inc.'s Operating Income Loss has declined by 168.0%.
- Historical annual values: Fiscal year 2025: -$49.33 million | Fiscal year 2024: -$51.52 million | Fiscal year 2023: -$33.92 million | Fiscal year 2022: -$29.91 million | Fiscal year 2021: -$32.48 million | Fiscal year 2020: -$32.49 million | Fiscal year 2019: -$26.65 million | Fiscal year 2018: -$18.41 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: